Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 3/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218839 | 0.91 | PTGDR (0.42) | PTGDRIKBKBRORCUTS2RALDH1A1 | |
| SCHEMBL6218902 | 0.91 | PTGDR (0.42) | PTGDRIKBKBRORCUTS2RALDH1A1 | |
| SCHEMBL6104724 | 0.83 | PTGDR (0.44) | PTGDRIKBKBHRH1CCR3PKM | |
| SCHEMBL6245802 | 0.83 | PTGDR (0.44) | PTGDRIKBKBHRH1CCR3PKM | |
| SCHEMBL6245804 | 0.83 | PTGDR (0.44) | PTGDRIKBKBHRH1CCR3PKM | |
| SCHEMBL6103410 | 0.83 | PTGDR (0.41) | PTGDRIKBKBHRH1CCR3RORC | |
| SCHEMBL6248851 | 0.82 | IKBKB (0.48) | PTGDRIKBKBHRH1CCR3RORC | |
| SCHEMBL6248847 | 0.82 | IKBKB (0.48) | PTGDRIKBKBHRH1CCR3RORC | |
| SCHEMBL6248849 | 0.82 | IKBKB (0.48) | PTGDRIKBKBHRH1CCR3RORC | |
| SCHEMBL6362089 | 0.80 | PTGDR (0.41) | PTGDRIKBKBUTS2RALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| CN-1681503-A | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
| EP-1539159-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004006926-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | MMP9, MMP2, MMP25 | PTGDR 1995/4885IKBKB 1562/4885HRH1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.